Conference on Chemoprevention of Prostate Cancer

描述(由申请人提供)：一年一度的前列腺癌化学预防国际会议及其作为同行评审的领先泌尿学杂志的CME附录出版的会议包括一个旨在满足社区泌尿科医生和肿瘤学家需求的继续医学教育(CME)计划。年度会议和经久不衰的教育期刊出版物都将专注于与医学界最相关的尖端数据，并促进基础和临床研究最活跃的人在这一前景广阔的领域推进和交流信息。以第一次会议为基础的教育出版物专门设计为对尽可能广泛的医学受众有用，它发表在该领域领先的同行评议医学期刊《泌尿学杂志》上。 该项目由伊恩·M·汤普森(Ian M.Thompson)指导，他是德克萨斯州圣安东尼奥的德克萨斯大学健康科学中心泌尿外科教授兼主任。汤普森博士是一位公认的领导者和贡献者，他推动了人们对前列腺癌治疗和研究新方法的理解，特别是在化学预防方面。 计划于2002年3月6日至8日举行的第一次会议将是在德克萨斯州圣安东尼奥举行的为期三天的专家会议，20-22名临床领导人将在圣安东尼奥评估和开发化学预防药物。随后的会议将在圣安东尼奥和弗吉尼亚州的麦克莱恩之间轮流举行。 该计划的具体目标如下： 回顾和评估前列腺癌化学预防基础和临床研究的最新数据和专家临床观点。 通过发布共识白皮书，向治疗前列腺癌患者和从事前列腺癌研究的泌尿科医生、肿瘤学家和其他临床医生传播与之相关的要点。 提供前列腺癌治疗中化学预防的信息平台，医生将利用该平台提供持续的医疗和患者教育，形式为会议在主要同行评议的医学期刊上发表的年度会议记录。

DESCRIPTION (provided by applicant): The annual International Conference on Chemoprevention of Prostate Cancer and its published proceedings as a peer-reviewed CME supplement to a leading peer-reviewed urology journal comprise a continuing medical education (CME) program designed to serve the needs of community-based urologists and oncologists. Both the annual conference and the enduring educational journal publications will focus on the cutting-edge data most relevant to the medical community, and facilitate advancing and communicating information on this promising field from those most active in basic and clinical research. The educational publication based on the first meeting is specifically designed to be useful to the broadest possible medical audience by its publication in the leading peer-reviewed medical journal in the field, The Journal of Urology. The program is directed by Ian M. Thompson, M.D., Professor and Chief, Division of Urology at The University of Texas Health Science Center in San Antonio, Texas. Dr. Thompson is a recognized leader and contributor to advancing understanding of new approaches to prostate cancer treatment and research, in particular in the area chemoprevention. The first meeting, planned for March 6-8, 2002, will be a three-day expert conference of 20-22 clinical leaders in the evaluation and development of chemopreventive agents in San Antonio, Texas. Subsequent meetings will alternate between San Antonio and McLean, Virginia. The specific objectives of the program are as follows: Review and assess recent data and expert clinical perspectives on basic and clinical research on chemoprevention of prostate cancer. Disseminate, through publication of consensus white papers, key points of alignment of relevance to urologists, oncologists and other clinicians treating prostate cancer patients and engaged in prostate cancer research. Provide a platform of information on chemoprevention in prostate cancer therapy that will be utilized by physicians providing ongoing medical and patient education, in the form of the annual published proceedings of the conference in leading peer-reviewed medical journals.